Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
07
10
2022
accepted:
14
04
2023
revised:
03
04
2023
medline:
14
7
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
B-raf inhibitors (BRAFi) are effective for BRAF-mutated papillary (PTC) and anaplastic (ATC) thyroid carcinomas, although acquired resistance impairs tumour cells' sensitivity and/or limits drug efficacy. Targeting metabolic vulnerabilities is emerging as powerful approach in cancer. In silico analyses identified metabolic gene signatures and Hif-1α as glycolysis regulator in PTC. BRAF-mutated PTC, ATC and control thyroid cell lines were exposed to HIF1A siRNAs or chemical/drug treatments (CoCl A specific metabolic gene signature was identified as a hallmark of BRAF-mutated tumours, which display a glycolytic phenotype, characterised by enhanced glucose uptake, lactate efflux and increased expression of Hif-1α-modulated glycolytic genes. Indeed, Hif-1α stabilisation counteracts the inhibitory effects of BRAFi on these genes and on cell viability. Interestingly, targeting metabolic routes with BRAFi and diclofenac combination we could restrain the glycolytic phenotype and synergistically reduce tumour cells' viability. The identification of a metabolic vulnerability of BRAF-mutated carcinomas and the capacity BRAFi and diclofenac combination to target metabolism open new therapeutic perspectives in maximising drug efficacy and reducing the onset of secondary resistance and drug-related toxicity.
Sections du résumé
BACKGROUND
B-raf inhibitors (BRAFi) are effective for BRAF-mutated papillary (PTC) and anaplastic (ATC) thyroid carcinomas, although acquired resistance impairs tumour cells' sensitivity and/or limits drug efficacy. Targeting metabolic vulnerabilities is emerging as powerful approach in cancer.
METHODS
In silico analyses identified metabolic gene signatures and Hif-1α as glycolysis regulator in PTC. BRAF-mutated PTC, ATC and control thyroid cell lines were exposed to HIF1A siRNAs or chemical/drug treatments (CoCl
RESULTS
A specific metabolic gene signature was identified as a hallmark of BRAF-mutated tumours, which display a glycolytic phenotype, characterised by enhanced glucose uptake, lactate efflux and increased expression of Hif-1α-modulated glycolytic genes. Indeed, Hif-1α stabilisation counteracts the inhibitory effects of BRAFi on these genes and on cell viability. Interestingly, targeting metabolic routes with BRAFi and diclofenac combination we could restrain the glycolytic phenotype and synergistically reduce tumour cells' viability.
CONCLUSION
The identification of a metabolic vulnerability of BRAF-mutated carcinomas and the capacity BRAFi and diclofenac combination to target metabolism open new therapeutic perspectives in maximising drug efficacy and reducing the onset of secondary resistance and drug-related toxicity.
Identifiants
pubmed: 37198319
doi: 10.1038/s41416-023-02282-2
pii: 10.1038/s41416-023-02282-2
pmc: PMC10338540
doi:
Substances chimiques
Diclofenac
144O8QL0L1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Protein Kinase Inhibitors
0
Glucose
IY9XDZ35W2
BRAF protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-265Informations de copyright
© 2023. The Author(s).
Références
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.
doi: 10.1016/j.cell.2014.09.050
Costa V, Esposito R, Ziviello C, Sepe R, Bim LV, Cacciola NA, et al. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma. Oncotarget. 2015;6:11242–51.
pubmed: 25803323
pmcid: 4484453
doi: 10.18632/oncotarget.3593
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13:472–82.
pubmed: 18538731
doi: 10.1016/j.ccr.2008.05.005
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27–47.
pubmed: 26771115
pmcid: 4715268
doi: 10.1016/j.cmet.2015.12.006
Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 2020;10:1797–807.
pubmed: 33139243
pmcid: 7710573
doi: 10.1158/2159-8290.CD-20-0844
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28.
pubmed: 33546704
pmcid: 7863491
doi: 10.1186/s12943-021-01316-8
Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30.
pubmed: 19872213
pmcid: 2140820
doi: 10.1085/jgp.8.6.519
Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell. 2013;23:302–15.
pubmed: 23477830
pmcid: 3635826
doi: 10.1016/j.ccr.2013.02.003
Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423–33. https://doi.org/10.1158/2159-8290.CD-13-0440 .
doi: 10.1158/2159-8290.CD-13-0440
pubmed: 24469106
pmcid: 4110245
Brummer C, Faerber S, Bruss C, Blank C, Lacroix R, Haferkamp S, et al. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma. Cancer Lett. 2019;442:453–63.
pubmed: 30481565
doi: 10.1016/j.canlet.2018.11.018
Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670–5.
pubmed: 7391842
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555–9.
pubmed: 19661383
pmcid: 2820374
doi: 10.1126/science.1174229
Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, et al. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab. 2011;96:E19–E30.
pubmed: 20926530
doi: 10.1210/jc.2010-1071
Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Mol Cancer. 2017;16:102.
pubmed: 28595656
pmcid: 5465587
doi: 10.1186/s12943-017-0667-y
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596–9.
pubmed: 20823850
pmcid: 2948082
doi: 10.1038/nature09454
Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, et al. A. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010;8:39.
pubmed: 20406486
pmcid: 2876068
doi: 10.1186/1479-5876-8-39
Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012;2:22.
pubmed: 22651703
pmcid: 3405466
doi: 10.1186/2191-219X-2-22
McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012;30:1628–34.
pubmed: 22454415
pmcid: 5950495
doi: 10.1200/JCO.2011.39.1938
Carlino MS, Saunders CA, Haydu LE, Menzies AM, Martin Curtis C Jr, Lebowitz PF, et al. [18]F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Eur J Cancer. 2013;49:395–402.
pubmed: 22981500
doi: 10.1016/j.ejca.2012.08.018
Chai YJ, Yi JW, Oh SW, Kim YA, Yi KH, Kim JH, et al. Upregulation of SLC2 (GLUT) family genes is related to poor survival outcomes in papillary thyroid carcinoma: analysis of data from The Cancer Genome Atlas. Surgery. 2017;161:188–94.
pubmed: 27842912
doi: 10.1016/j.surg.2016.04.050
Ma B, Jiang H, Wen D, Hu J, Han L, Liu W, et al. Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer. J Clin Endocrinol Metab. 2019;104:3713–25.
pubmed: 30942873
doi: 10.1210/jc.2018-02686
Suh HY, Choi H, Paeng JC, Cheon GJ, Chung JK, Kang KW. Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer. BMC Cancer. 2019;19:1260.
pubmed: 31888560
pmcid: 6937781
doi: 10.1186/s12885-019-6482-7
Xu M, Sun T, Wen S, Zhang T, Wang X, Cao Y, et al. Characteristics of lipid metabolism-related gene expression-based molecular subtype in papillary thyroid cancer. Acta Biochim Biophys Sin. 2020;52:1166–70.
pubmed: 32880619
doi: 10.1093/abbs/gmaa092
Ban EJ, Kim D, Kim JK, Kang SW, Lee J, Jeong JJ, et al. Lactate dehydrogenase a as a potential new biomarker for thyroid cancer. Endocrinol Metab. 2021;36:96–105.
doi: 10.3803/EnM.2020.819
Hou X, Shi X, Zhang W, Li D, Hu L, Yang J, et al. LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma. Cell Death Dis. 2021;12:347.
pubmed: 33795650
pmcid: 8017009
doi: 10.1038/s41419-021-03641-8
Xu F, Xu H, Li Z, Huang Y, Huang X, Li Y, et al. Glycolysis-based genes are potential biomarkers in thyroid cancer. Front Oncol. 2021;11:534838.
pubmed: 33981593
pmcid: 8107473
doi: 10.3389/fonc.2021.534838
Wen S, Luo Y, Wu W, Zhang T, Yang Y, Ji Q, et al. Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer. Acta Biochim Biophys Sin. 2021;53:1579–89.
pubmed: 34693452
doi: 10.1093/abbs/gmab145
Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharm. 2011;82:201–9.
pubmed: 21635872
doi: 10.1016/j.bcp.2011.05.015
Sanchez JN, Wang T, Cohen MS. BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs. 2018;78:549–66.
pubmed: 29488071
pmcid: 6080616
doi: 10.1007/s40265-018-0884-8
Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
pubmed: 22395615
doi: 10.1038/ncomms1727
Gottfried E, Lang SA, Renner K, Bosserhoff A, Gronwald W, Rehli M, et al. New aspects of an old drug-diclofenac targets MYC and glucose metabolism in tumor cells. PLoS ONE. 2013;8:e66987.
pubmed: 23874405
pmcid: 3706586
doi: 10.1371/journal.pone.0066987
Federico A, Rienzo M, Abbondanza C, Costa V, Ciccodicola A, Casamassimi A. Pan-cancer mutational and transcriptional analysis of the integrator complex. Int J Mol Sci. 2017;18:936.
pubmed: 28468258
pmcid: 5454849
doi: 10.3390/ijms18050936
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–40.
pubmed: 19910308
doi: 10.1093/bioinformatics/btp616
Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, et al. Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling. Mol Cell. 2015;59:345–58.
pubmed: 26145173
pmcid: 4530073
doi: 10.1016/j.molcel.2015.05.037
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–7.
pubmed: 22455463
pmcid: 3339379
doi: 10.1089/omi.2011.0118
Stathias V, Turner J, Koleti A, Vidovic D, Cooper D, Fazel-Najafabadi M, et al. LINCS Data Portal 2.0: next generation access point for perturbation-response signatures. Nucleic Acids Res. 2020;48:D431–D439.
pubmed: 31701147
doi: 10.1093/nar/gkz1023
Niepel M, Hafner M, Mills CE, Subramanian K, Williams EH, Chung M, et al. A multi-center study on the reproducibility of drug-response assays in mammalian cell lines. Cell Syst. 2019;9:35–48.e5.
pubmed: 31302153
pmcid: 6700527
doi: 10.1016/j.cels.2019.06.005
Costa V, Conte I, Ziviello C, Casamassimi A, Alfano G, Banfi S, et al. Identification and expression analysis of novel Jakmip1 transcripts. Gene. 2007;402:1–8.
pubmed: 17761393
doi: 10.1016/j.gene.2007.07.001
Aprile M, Cataldi S, Ambrosio MR, D’Esposito V, Lim K, Dietrich A, et al. PPARγΔ5, a naturally occurring dominant-negative splice isoform, impairs PPARγ function and adipocyte differentiation. Cell Rep. 2018;25:1577–1592.e6.
pubmed: 30404011
doi: 10.1016/j.celrep.2018.10.035
Esposito R, Esposito D, Pallante P, Fusco A, Ciccodicola A, Costa V. Oncogenic properties of the antisense lncRNA COMET in BRAF- and RET-driven papillary thyroid carcinomas. Cancer Res. 2019;79:2124–35.
pubmed: 30862713
doi: 10.1158/0008-5472.CAN-18-2520
Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739–43.
pubmed: 35580060
pmcid: 9252834
doi: 10.1093/nar/gkac382
Ianevski A, Giri AK, Gautam P, Kononov A, Potdar S, Saarela J, et al. Prediction of drug combination effects with a minimal set of experiments. Nat Mach Intell. 2019;1:568–77.
pubmed: 32368721
pmcid: 7198051
doi: 10.1038/s42256-019-0122-4
Coelho RG, Fortunato RS, Carvalho DP. Metabolic reprogramming in thyroid carcinoma. Front Oncol. 2018;8:82.
pubmed: 29629339
pmcid: 5876306
doi: 10.3389/fonc.2018.00082
Nahm JH, Kim HM, Koo JS. Glycolysis-related protein expression in thyroid cancer. Tumour Biol. 2017;39:1010428317695922.
pubmed: 28347233
doi: 10.1177/1010428317695922
Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature. 2014;508:108–12.
pubmed: 24670634
pmcid: 4012432
doi: 10.1038/nature13110
Onodera Y, Nam JM, Bissell MJ. Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Invest. 2014;124:367–84.
pubmed: 24316969
doi: 10.1172/JCI63146
de la Cruz-López KG, Castro-Muñoz LJ, Reyes-Hernández DO, García-Carrancá A, Manzo-Merino J. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 2019;9:1143.
pubmed: 31737570
pmcid: 6839026
doi: 10.3389/fonc.2019.01143
Payen VL, Mina E, Van Hée VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48–66.
pubmed: 31395464
doi: 10.1016/j.molmet.2019.07.006
Tanner LB, Goglia AG, Wei MH, Sehgal T, Parsons LR, Park JO, et al. Four key steps control glycolytic flux in mammalian cells. Cell Syst. 2018;7:49–62.e8.
pubmed: 29960885
pmcid: 6062487
doi: 10.1016/j.cels.2018.06.003
Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013;153:56–69.
pubmed: 23540690
pmcid: 3775362
doi: 10.1016/j.cell.2013.03.004
Miranda-Gonçalves V, Lameirinhas A, Henrique R, Jerónimo C. Metabolism and epigenetic interplay in cancer: regulation and putative therapeutic targets. Front Genet. 2018;9:427.
Mehta A, Patel BM. Therapeutic opportunities in colon cancer: focus on phosphodiesterase inhibitors. Life Sci. 2019;230:150–61.
pubmed: 31125564
doi: 10.1016/j.lfs.2019.05.043
Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997;94:6658–63.
pubmed: 9192621
pmcid: 21214
doi: 10.1073/pnas.94.13.6658
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275:21797–800.
pubmed: 10823814
doi: 10.1074/jbc.C000023200
Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007;12:108–13.
pubmed: 17692803
pmcid: 3215289
doi: 10.1016/j.ccr.2007.07.006
Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27:7381–93.
pubmed: 17785433
pmcid: 2169056
doi: 10.1128/MCB.00440-07
Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–64.
pubmed: 16904903
doi: 10.1016/j.semcancer.2006.07.014
Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15:6479–83.
pubmed: 19861459
pmcid: 2783410
doi: 10.1158/1078-0432.CCR-09-0889
Qu Y, Yang Q, Liu J, Shi B, Ji M, Li G, et al. c-Myc is required for BRAF
pubmed: 28656062
pmcid: 5485424
doi: 10.7150/thno.19884
Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432.
pubmed: 20003271
pmcid: 2797529
doi: 10.1186/1471-2407-9-432
Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013;3:520–33.
pubmed: 23365119
pmcid: 3651738
doi: 10.1158/2159-8290.CD-12-0531
Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013;368:684–5.
pubmed: 23406047
doi: 10.1056/NEJMc1215697
Marten KA, Gudena VK. Use of vemurafenib in anaplastic thyroid carcinoma: a case report. Cancer Biol Ther. 2015;16:1430–3.
pubmed: 26176686
pmcid: 4846098
doi: 10.1080/15384047.2015.1071734
Prager GW, Koperek O, Mayerhoefer ME, Muellauer L, Wrba F, Niederle B, et al. Sustained response to vemurafenib in a BRAF
pubmed: 27532222
doi: 10.1089/thy.2015.0575
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, et al. Pan-cancer efficacy of vemurafenib in BRAF
pubmed: 32029534
pmcid: 7196502
doi: 10.1158/2159-8290.CD-19-1265
Albano F, Arcucci A, Granato G, Romano S, Montagnani S, De Vendittis E, et al. Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines. Biochimie. 2013;95:934–45.
pubmed: 23274131
doi: 10.1016/j.biochi.2012.12.012
Pandey SK, Yadav S, Goel Y, Temre MK, Singh VK, Singh SM. Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics. J Theor Biol. 2019;21:117–25.
doi: 10.1016/j.jtbi.2019.01.020
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877–85.
pubmed: 12942121
pmcid: 2394471
doi: 10.1038/sj.bjc.6601205
Zhang X, Zhao H, Li Y, Xia D, Yang L, Mam Y, et al. The role of YAP/TAZ activity in cancer metabolic reprogramming. Mol Cancer. 2018;17:134.
Klaus A, Fathi O, Tatjana TW, Bruno N, Oskar K. Expression of hypoxia-associated protein HIF-1α in follicular thyroid cancer is associated with distant metastasis. Pathol Oncol Res. 2018;24:289–96.
pubmed: 28474313
doi: 10.1007/s12253-017-0232-4
Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S, Moreno-Sánchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009;9:1084–101.
pubmed: 19689405
doi: 10.2174/138955709788922610
Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207–14.
pubmed: 22398146
pmcid: 3437546
doi: 10.1016/j.tips.2012.01.005
Gottlieb E, Tomlinson IPM. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer. 2005;5:857–66.
pubmed: 16327764
doi: 10.1038/nrc1737
Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller K, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell. 2007;11:407–20.
pubmed: 17482131
doi: 10.1016/j.ccr.2007.04.001
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–85.
pubmed: 16517405
doi: 10.1016/j.cmet.2006.02.002
Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 2007;67:3177–84.
pubmed: 17409425
doi: 10.1158/0008-5472.CAN-06-3312
Wang JZ, Zhu W, Han J, Yang X, Zhou R, Lu HC, et al. The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun. 2021;41:560–75.
doi: 10.1002/cac2.12158
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
pubmed: 21639808
pmcid: 3549296
doi: 10.1056/NEJMoa1103782
Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36.
pubmed: 26287849
pmcid: 4971773
doi: 10.1056/NEJMoa1502309
Rordorf CM, Choi L, Marshall P, Mangold JB. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44:1247–66.
pubmed: 16372823
doi: 10.2165/00003088-200544120-00004
Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet. 1997;33:184–213.
pubmed: 9314611
doi: 10.2165/00003088-199733030-00003
FDA, Prescribing Information “diclofenac Sodium Enteric-coated Tablets. 2018; https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019201s038lbl.pdf .
Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharm. 1979;16:405–10.
doi: 10.1007/BF00568201
Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharm. 1983;25:389–94.
doi: 10.1007/BF01037953
Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet. 2004;43:467–78.
pubmed: 15139795
doi: 10.2165/00003088-200443070-00003
Claps G, Faouzi S, Quidville V, Chehade F, Shen S, Vagner S, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. 2022;19:749–62.
pubmed: 36207413
doi: 10.1038/s41571-022-00686-2
Comandatore A, Franczak M, Smolenski RT, Morelli L, Peters GJ, Giovannetti E. Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers. Semin Cancer Biol. 2022;86:93–100.
pubmed: 36096316
doi: 10.1016/j.semcancer.2022.09.001
Chirasani SR, Leukel P, Gottfried E, Hochrein J, Stadler K, Neumann B, et al. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. Int J Cancer. 2013;132:843–53.
pubmed: 22752934
doi: 10.1002/ijc.27712
Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing drugs in oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016;10:610.
pubmed: 26823679
pmcid: 4720497